62 Single-centre DGH experience of using immunotherapy for malignant mesothelioma

The treatment options for mesothelioma has expanded with the availability of immune checkpoint inhibitors; 2nd line Nivolumab in 2020 (interim COVID NICE guidance) and 1st line Ipilimumab& Nivolumab in 2022. This audit provides an overview of our initial experience with these drugs for mesothelioma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mesothelioma Source Type: research